COSCIENS Biopharma Inc.
CSCIF
$2.08
-$0.08-3.92%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 68.39% | -89.94% | -160.89% | -190.57% | -38.84% |
| Total Depreciation and Amortization | -40.08% | -23.87% | -9.47% | -70.24% | 1,040.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -105.86% | 118.13% | 132.63% | 333.82% | 99.51% |
| Change in Net Operating Assets | 123.05% | -233.39% | 238.09% | -50.17% | -4,288.30% |
| Cash from Operations | 91.31% | -220.16% | 21.01% | -132.75% | -129.88% |
| Capital Expenditure | -- | 68.79% | -9.04% | 56.36% | -1,355.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 0.00% | 21,500.00% |
| Cash from Investing | -95.18% | -100.19% | -9.04% | 55.80% | 930.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 25.44% | 48.41% | -112.77% | 57.59% | -245.45% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 54.79% | 15.08% | -112.77% | 17.21% | -469.70% |
| Foreign Exchange rate Adjustments | -166.67% | 364.18% | 144.78% | -160.27% | 2,700.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 89.64% | -118.21% | 16.93% | -143.21% | -127.58% |